BOSTON and LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback